RESUMO
A dithiosemicarbazone of 13% starch dialdehyde (DASTSC) was active against Mycobacterium tuberculosis under laboratory tests. M. tuberculosis strains sensitive and resistant to isoniazid (INH) were developed at the concentrations of 2.5 x 10(-4)-5.0 x 10(-1) mg/cm3 on a solid Löwenstein-Jensen medium and treated with 1-25 mg/cm3 of DASTSC in all mutual combinations of concentrations. Both, sensitive and resistant to INH strains reacted to DASTSC. The growth of strains could be completely inhibited as proved in eight-week tests. The inhibition was non-linearly dependent on concentration of DASTSC. The lowest and the highest concentrations of DASTSC did not inhibit the M. tuberculosis growth. The doses of DASTSC were optimised.
Assuntos
Antituberculosos/farmacologia , Mycobacterium tuberculosis/efeitos dos fármacos , Amido/farmacologia , Tiossemicarbazonas/farmacologia , Antituberculosos/química , Relação Dose-Resposta a Droga , Amido/análogos & derivados , Amido/química , Tiossemicarbazonas/químicaRESUMO
Co (II), Cu (II) and Ni (II) complexes of starch dialdehyde dithiosemicarbazone (DASTSC) of low (approximately 15%) degree of oxidation were prepared and their tuberculostatic activity was tested in vitro against isoniazid-sensitive and isoniazid-resistant strains of Mycobacterium tuberculosis. In 10-week lasting tests the DASTSC complex with Ni (II) was tuberculostatic to a similar extent as was the free ligand, whereas the Co (II) and Cu (II) complexes inhibited the growth of M. tuberculosis more efficiently. It was also proved that the corresponding non-co-ordinated metal salts were inactive to both strains of M. tuberculosis.
Assuntos
Antituberculosos/síntese química , Quelantes/química , Cobalto , Cobre , Níquel , Compostos Organometálicos/síntese química , Polissacarídeos/síntese química , Polissacarídeos/farmacologia , Tiossemicarbazonas/síntese química , Tiossemicarbazonas/farmacologia , Antituberculosos/farmacologia , Farmacorresistência Bacteriana , Técnicas In Vitro , Isoniazida/farmacologia , Ligantes , Mycobacterium tuberculosis/efeitos dos fármacos , Compostos Organometálicos/farmacologiaRESUMO
Pefloxacin, a 4-quinolone derivative, was administered in the dose of 800-1200 mg for the mean of 12 days to 24 patients with respiratory tract infection complicating chronic bronchial asthma or chronic obstructive lung disease. Patients with positive sputum culture and bacteria sensitive to pefloxacin were included in the study. Total eradication of the offending microorganisms was achieved in 54% of patients, and partial--in the next 20%. A poor efficacy of pefloxacin against Streptococcus species has been confirmed. In a few cases we have observed the development of resistance of isolated bacteria to pefloxacin during the course of treatment.